Search Results

Zerion Pharma A/S (“ZERION”) today announces an exclusive partnership with dsm-firmenich to take advantage of ZERION’s expertise and its Dispersome®

A new study published in the BMJ found strong financial ties between the pharmaceutical industry and physicians serving as panelists and task force members of the DSM-5.

Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce today that they have entered into an agreement with the KTH Royal Institute of Technology to utilise KTH’s state-of-the-art supercomputer resources for analysing protein structures.

Sirtex Medical (“Sirtex”) announced today the establishment of a collaboration and exclusive worldwide distribution agreement with Magle Group, a Sweden-based contract development and manufacturing organization as well as Degradable Starch Microspheres (DSM) sales and marketing company.

Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, comments on the findings from a recently published paper in Nature Medicine which reported that those infected with COVID-19 are at increased risk of long-term neurologic disorders that persist post infection.

RaySearch Laboratories AB is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* - including the new ARTemis* OART solution under development - in combination with the Radixact® Treatment Delivery System from Accuray.

Cerevance today announced plans to present an oral presentation at the upcoming 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium, taking place in Cambridge, United Kingdom, September 10 – 13th, 2023.

Royal Biologics, Inc ., a company specializing in Advanced Cellular & Autologous Technologies for Enhanced Surgical Solutions, today announced the commercial launch of BIO-REIGN the first natural hyper-crosslinked carbohydrate polymer bone graft substitute (BGS).